Delivering potentially transformational medicines through R&D innovation in Oncology

Asthma management: it’s time to get personal

TB: uniting scientists to tackle one of the world’s biggest killers

Tuberculosis (TB) is one of the top ten causes of deaths worldwide.

Making the switch: how we’re improving access to proven medicines

Switching a medicine from prescription OTC places the power of managing everyday health conditions with the patient.

The lung microbiome and the future management of respiratory disease

Your lungs are full of micro-organisms. Some are welcome guests and some are uninvited gate-crashers

Revealing the beautiful complexity of the immune system

David Roth works in immunology research and development. Here he talks to us about the complexity of the body’s defence system and how we’re working to unlock its hidden secrets to help bring new medicines to patients.

GSK’s SAM technology could revolutionise vaccines

Our focus on developing the next generation of antibiotics

Delivering potentially transformational medicines through R&D innovation in Oncology

Axel Hoos, SVP, Oncology R&D, explains how GSK is driving innovation in Oncology R&D

How do you test medicines in the real world?

For decades, randomised clinical trials have been a cornerstone of pharmaceutical science, reassuring patients that their medicines have been thoroughly tested. But there’s a wide world beyond the research clinic doors and the data collected in these highly controlled environments are just the first chapter of a rich story.

The vaccines of tomorrow

Join our leading scientists as they go behind the science of vaccine technology.

Inclusive design: making our differences invisible

Great design is almost invisible, it’s something that is seamless and frictionless. But for anyone who has experienced poor design, the frustration and hardship are all too evident.

Unravelling the mysteries of the human genome with functional genomics

Why collaboration is essential to achieving new breakthroughs in vaccines

Tackling tomorrow’s health challenges today

Our Chief Scientist, Rino Rappuoli, explains how science is helping create the vaccines of tomorrow

From eucalyptus toothpaste to a brew for the flu: tailoring products to different tastes

Find out where these ideas for different tastes come from and how they make it onto the shelf.

STEM – inspiring tomorrow’s science and engineering superstars

Meet this year’s GSK UK Young Scientist and Engineers of the Year.

We need more women in science to create the inclusive technologies of the future

Nidhi Aggarwal, Global Packaging Development Manager, Consumer Healthcare, tells how she reached her current role and explains why we need more diversity of thought in science and applied fields.

COPD is more than a lung disease

Using the immune system to fight cancer

From bench to bedside: lessons in converting science into impact

Pauline Williams, Head of Global Health R&D, shares a unique perspective on what it takes to research new treatments and deliver them to patients around the world.

How a chance encounter led to a world-first toothpaste

Did you know that NovaMin, one of the key technologies in our toothpaste, is actually a bioactive glass most commonly used to repair bones?

Inside the Open Lab

How does the Tres Cantos Open Lab offer top international scientists and academics the opportunity to pursue their own projects as part of an integrated team?

You, me and 23andMe: discovering new medicines through genetics

Explore how our new collaboration with 23andMe could help unlock the medicines of tomorrow.

How do consumer insights fuel our innovation?

How genomics is driving a new era of drug discovery

How are we redefining research in HIV?

Shari Gordon works in the HIV Cure Center in North Carolina, a public-private company with one goal: discovering a cure for HIV/AIDS.

Following the journey of a respiratory medicine

Elaine Jones explains how her passion for helping respiratory patients live every breath motivates her in developing new medicines.

Lupus: the search for a cure continues

Doctors and their patients face an ongoing battle to manage this chronic and sometimes debilitating and life-threatening condition. See how we’re trying to help.

COPD for John just means doing everything at a slower pace

Meet John - at 80 years old, he refuses to let COPD get in the way of living the life he wants to.

Making the Ellipta® inhaler a reality

Overcoming the challenges of COPD to fulfil a lifelong dream

The science of shopping

Every day millions of consumers use our products. Different countries have different needs and consumers’ shopping habits vary hugely.

I control my asthma, it doesn’t control me

Jamie from our Montrose site tells how he managed his asthma to conquer Mount Kenya

Thank you for calling GSK. Meet Paul, the voice at the end of the line.

When you call us, who’s the voice at the end of the line? Paul tells his story from scientist to sympathetic ear.

You'll outgrow some childhood habits, but vaccination is for life

Infectious diseases remain just as serious throughout adulthood and vaccines remain the most effective protection we have against them.

How curious minds saved a medicine from being left in the lab

Does lupus really know no boundaries?

Giving a bit back – Christine’s experience of clinical research

For Christine even gentle exercise like jogging and walking her dogs around the park were a struggle. She just could not breathe properly.

30 years and counting: the fight against HIV

How to find a treatment for a disease with no idea what that disease actually is.

The digitalisation lab: bringing the digital age to manufacturing

We are developing world-class manufacturing innovation to help us bring medicines and consumer healthcare products to people.

COPD: Our relentless pursuit for better breathing

Every person with COPD is different, with different needs, different challenges and different goals. See how we're innovating to determine the right treatment for the right patient.

Getting on target in autoimmune diseases

How smart is your inhaler?

Can social media help us hear patients?

Understanding the benefits and risks of medicine from a patient’s point of view is important to the evaluation of our medicines.

Don’t forget the pharmacists

Dr. Sharmila Ramachandran and Dr. Aruni Mulgirigama talk about the essential role of pharmacists in asthma care

Scientists or detectives? Seeking new clues in COPD

It is now widely accepted that COPD is not a uniform disease, but effects of the disease can impact people differently.

Inhaler innovation: more than a simple piece of plastic

At first glance, an inhaler may look like a simple piece of plastic. But inside, a complicated process and an internal ‘engine’ operate seamlessly...

The design behind the device

An 'everyday' world first in clinical trials

Vaccine manufacture: it’s complicated

Vaccine manufacture can take anywhere between 6 and 26 months. That’s not to mention the time required to research and develop a new vaccine, which can take up to 30 years.

Beyond manufacturing in Chile and Madagascar

GSK Vaccines sent two vaccine manufacturing teams to South America and Africa to better understand the impact of their daily work.

Living with lupus – a patient perspective

Beth, a lupus patient, provides insights into the day-to-day challenges of living with this chronic condition.

Turbocharging the effect of vaccines

When extracted and purified, a compound from the soap bark tree can be mixed with other ingredients to create an ‘adjuvant’, turbocharging the body's immune defences.

Outgrowing asthma

Targeting the immune system through open innovation

Cell and gene therapy: a new era of medicine

If we can pinpoint a faulty gene and correct it, could we potentially find a way to cure genetic diseases?

Neuroscience: on the brain

The number of people living with dementia worldwide is set to treble by 2050 to 135 million, according to the World Health Organization.

Eggs in manufacturing

Chickens. Where would we be without them? Well for one thing, we wouldn’t have nearly as many influenza vaccines as we need.